Omeros (OMER) closed at $16.68 on November 16, 2026, down 4.6% from the previous close, on volume of 1,272,223 shares (30-day average 1,017,516).
Data as of November 16, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 16, 2026 | Call Spread | 20-Nov-2618 : 20 C | 200 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 16, 2026. See the largest for 5, 30, 60 and 90 days
Brandon Folkes Reiterates Buy on YARTEMLEA Growth Potential, Maintains $33 Price Target
TipRanks (Tue, 17-Nov 11:15 AM ET)
Cantor Fitzgerald Remains a Buy on Omeros (OMER)
TipRanks (Tue, 17-Nov 8:16 AM ET)
Omeros Non-GAAP EPS of $0.06 beats by $0.08, revenue of $35.9M misses by $1.37M
Seeking Alpha News (Mon, 16-Nov 4:06 PM ET)
Omeros Corporation Reports Third Quarter 2026 Financial Results
Business Wire (Mon, 16-Nov 4:02 PM ET)
Here are the major earnings after the close Monday
Seeking Alpha News (Mon, 16-Nov 10:00 AM ET)
Earnings Week Ahead: NVDA, WMT, TGT, DIS, BABA, BIDU, HD, and more
Seeking Alpha News (Sun, 15-Nov 8:07 AM ET)
Globe Newswire (Tue, 10-Nov 5:48 PM ET)
Omeros Corporation to Announce Third Quarter Financial Results on November 16, 2026
Business Wire (Tue, 10-Nov 4:02 PM ET)
Business Wire (Fri, 16-Oct 6:20 AM ET)
Surging YARTEMLEA Revenues and Bold Debt Reduction Mark Omeros’ Transformative Quarter
Market Chameleon (Thu, 13-Aug 6:32 AM ET)
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
Omeros trades on the NASDAQ stock market under the symbol OMER.
As of November 17, 2026, OMER stock price declined to $13.80 with 3,854,107 million shares trading.
OMER has a beta of 2.80, meaning it tends to be more sensitive to market movements. OMER has a correlation of 0.15 to the broad based SPY ETF.
OMER has a market cap of $998.78 million. This is considered a Small Cap stock.
Last quarter Omeros reported $36 million in Revenue and $.06 earnings per share. This fell short of revenue expectation by $-59,336 and exceeded earnings estimates by $.09.
In the last 3 years, OMER traded as high as $21.24 and as low as $1.49.
The top ETF exchange traded funds that OMER belongs to (by Net Assets): VTI, IWM, VXF, BRNY, XPH.
OMER has outperformed the market in the last year with a return of +75.3%, while the SPY ETF gained +9.7%. However, in the most recent history, OMER shares have underperformed the stock market with its stock returning -19.7% in the last 3 month period and -22.6% for the last 2 week period, while SPY has returned -5.8% and -3.0%, respectively.
OMER support price is $15.99 and resistance is $17.37 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OMER shares will trade within this expected range on the day.